Gambling, Resorts & Casinos
Build Your Comparison
Side-by-side financial analysisStock Comparison
ROLR vs GENI vs SRAD vs DKNG vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Internet Content & Information
Software - Application
Gambling, Resorts & Casinos
Beverages - Non-Alcoholic
ROLR vs GENI vs SRAD vs DKNG vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Gambling, Resorts & Casinos | Internet Content & Information | Software - Application | Gambling, Resorts & Casinos | Beverages - Non-Alcoholic |
| Market Cap | $57M | $1.76B | $4.73B | $14.38B | $355.61B |
| Revenue (TTM) | $17M | $713M | $1.33B | $6.29B | $49.28B |
| Net Income (TTM) | $1M | $-159M | $70M | $59M | $13.70B |
| Gross Margin | 49.6% | 22.6% | 38.2% | 41.8% | 61.7% |
| Operating Margin | -34.5% | -18.3% | 9.3% | 0.6% | 29.3% |
| Forward P/E | 17.6x | — | 40.3x | 122.9x | 25.3x |
| Total Debt | $807K | $30M | $63M | $1.93B | $45.49B |
| Cash & Equiv. | $2M | $281M | $365M | $1.60B | $10.27B |
ROLR vs GENI vs SRAD vs DKNG vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 24 | Jun 26 | Return |
|---|---|---|---|
| High Roller Technol… (ROLR) | 100 | Infinity | +Infinity% |
| Genius Sports Limit… (GENI) | 100 | 89.9 | -10.1% |
| Sportradar Group AG (SRAD) | 100 | 137.5 | +37.5% |
| DraftKings Inc. (DKNG) | 100 | 84.1 | -15.9% |
| The Coca-Cola Compa… (KO) | 100 | 114.0 | +14.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ROLR vs GENI vs SRAD vs DKNG vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ROLR is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.16 vs KO's 2.26
- Lower P/E (17.6x vs 25.3x), PEG 0.16 vs 2.26
- +137.8% vs SRAD's -36.9%
GENI ranks third and is worth considering specifically for income & stability.
- Dividend streak 1 yrs, beta 1.59
- 31.0% revenue growth vs ROLR's -26.6%
SRAD is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.65, Low D/E 6.4%, current ratio 1.17x
- Beta 0.65, current ratio 1.17x
- Beta 0.65 vs ROLR's 2.73, lower leverage
DKNG is the clearest fit if your priority is growth exposure.
- Rev growth 27.0%, EPS growth 99.2%, 3Y rev CAGR 39.3%
KO carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 121.1% 10Y total return vs DKNG's 195.9%
- 27.8% margin vs GENI's -22.3%
- 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
- 13.1% ROA vs GENI's -15.4%, ROIC 15.8% vs -16.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.0% revenue growth vs ROLR's -26.6% | |
| Value | Lower P/E (17.6x vs 25.3x), PEG 0.16 vs 2.26 | |
| Quality / Margins | 27.8% margin vs GENI's -22.3% | |
| Stability / Safety | Beta 0.65 vs ROLR's 2.73, lower leverage | |
| Dividends | 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +137.8% vs SRAD's -36.9% | |
| Efficiency (ROA) | 13.1% ROA vs GENI's -15.4%, ROIC 15.8% vs -16.6% |
ROLR vs GENI vs SRAD vs DKNG vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ROLR vs GENI vs SRAD vs DKNG vs KO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 5 of 6 categories
ROLR leads 0 • GENI leads 0 • SRAD leads 0 • DKNG leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 2890.9x ROLR's $17M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to GENI's -22.3%. On growth, GENI holds the edge at +30.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $17M | $713M | $1.3B | $6.3B | $49.3B |
| EBITDAEarnings before interest/tax | -$6M | -$54M | $308M | $313M | $15.5B |
| Net IncomeAfter-tax profit | $1M | -$159M | $70M | $59M | $13.7B |
| Free Cash FlowCash after capex | -$3M | $16M | $363M | $679M | $12.6B |
| Gross MarginGross profit ÷ Revenue | +49.6% | +22.6% | +38.2% | +41.8% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -34.5% | -18.3% | +9.3% | +0.6% | +29.3% |
| Net MarginNet income ÷ Revenue | +5.9% | -22.3% | +5.2% | +0.9% | +27.8% |
| FCF MarginFCF ÷ Revenue | -17.2% | +2.2% | +27.3% | +10.8% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -50.3% | +30.5% | +13.2% | +16.8% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.6% | -6.0% | -128.5% | +157.7% | +18.2% |
Valuation Metrics
Evenly matched — SRAD and DKNG each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 17.6x trailing earnings, ROLR trades at a 62% valuation discount to SRAD's 46.1x P/E. Adjusting for growth (PEG ratio), ROLR offers better value at 0.16x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $57M | $1.8B | $4.7B | $14.4B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $56M | $1.5B | $4.4B | $14.7B | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | 17.64x | -15.57x | 46.09x | -3580.25x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 40.28x | 122.88x | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | 0.16x | — | 0.81x | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | — | 21.46x | 56.63x | 26.39x |
| Price / SalesMarket cap ÷ Revenue | 2.78x | 2.63x | 3.30x | 2.37x | 7.42x |
| Price / BookPrice ÷ Book value/share | 6.36x | 2.41x | 4.52x | 22.77x | 10.40x |
| Price / FCFMarket cap ÷ FCF | — | 27.33x | 10.70x | 22.20x | 67.15x |
Profitability & Efficiency
KO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-22 for GENI. GENI carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to DKNG's 3.06x. On the Piotroski fundamental quality scale (0–9), DKNG scores 7/9 vs GENI's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.9% | -22.2% | +7.3% | +7.9% | +41.1% |
| ROA (TTM)Return on assets | +4.6% | -15.4% | +2.7% | +1.3% | +13.1% |
| ROICReturn on invested capital | -119.9% | -16.6% | +12.9% | -0.9% | +15.8% |
| ROCEReturn on capital employed | -63.7% | -15.3% | +5.3% | -0.6% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.08x | 0.04x | 0.06x | 3.06x | 1.33x |
| Net DebtTotal debt minus cash | -$1M | -$250M | -$302M | $330M | $35.2B |
| Cash & Equiv.Liquid assets | $2M | $281M | $365M | $1.6B | $10.3B |
| Total DebtShort + long-term debt | $807,000 | $30M | $63M | $1.9B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -17.49x | -75.96x | 2.02x | 4.48x | 10.70x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $3,776 for GENI. Over the past 12 months, ROLR leads with a +137.8% total return vs SRAD's -36.9%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs GENI's 4.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +190.0% | -36.5% | -31.4% | -18.7% | +20.3% |
| 1-Year ReturnPast 12 months | +137.8% | -34.6% | -36.9% | -23.6% | +17.2% |
| 3-Year ReturnCumulative with dividends | — | +13.4% | +28.7% | +13.9% | +47.0% |
| 5-Year ReturnCumulative with dividends | — | -62.2% | -36.2% | -42.7% | +65.6% |
| 10-Year ReturnCumulative with dividends | — | -31.5% | -36.2% | +195.9% | +121.1% |
| CAGR (3Y)Annualised 3-year return | — | +4.3% | +8.8% | +4.4% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than ROLR's 2.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs ROLR's 18.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.73x | 1.59x | 0.65x | 0.87x | -0.20x |
| 52-Week HighHighest price in past year | $33.68 | $13.73 | $32.22 | $48.78 | $84.04 |
| 52-Week LowLowest price in past year | $1.16 | $3.83 | $11.66 | $20.46 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +18.9% | +49.9% | +49.6% | +59.5% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 60.9 | 73.2 | 72.9 | 72.1 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 2.7M | 5.4M | 3.8M | 12.1M | 12.7M |
Analyst Outlook
KO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: GENI as "Buy", SRAD as "Buy", DKNG as "Buy", KO as "Buy". Consensus price targets imply 37.2% upside for GENI (target: $9) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $9.40 | $21.05 | $35.75 | $86.13 |
| # AnalystsCovering analysts | — | 19 | 20 | 48 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 1 | — | — | 56 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +2.5% | +5.8% | +0.2% |
KO leads in 5 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
ROLR vs GENI vs SRAD vs DKNG vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ROLR or GENI or SRAD or DKNG or KO a better buy right now?
For growth investors, Genius Sports Limited (GENI) is the stronger pick with 31.
0% revenue growth year-over-year, versus -26. 6% for High Roller Technologies, Inc. (ROLR). High Roller Technologies, Inc. (ROLR) offers the better valuation at 17. 6x trailing P/E, making it the more compelling value choice. Analysts rate Genius Sports Limited (GENI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ROLR or GENI or SRAD or DKNG or KO?
On trailing P/E, High Roller Technologies, Inc.
(ROLR) is the cheapest at 17. 6x versus Sportradar Group AG at 46. 1x. On forward P/E, The Coca-Cola Company is actually cheaper at 25. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Sportradar Group AG wins at 0. 71x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ROLR or GENI or SRAD or DKNG or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -62. 2% for Genius Sports Limited (GENI). Over 10 years, the gap is even starker: DKNG returned +195. 9% versus SRAD's -36. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ROLR or GENI or SRAD or DKNG or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus High Roller Technologies, Inc. 's 2. 73β — meaning ROLR is approximately -1462% more volatile than KO relative to the S&P 500. On balance sheet safety, Genius Sports Limited (GENI) carries a lower debt/equity ratio of 4% versus 3% for DraftKings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ROLR or GENI or SRAD or DKNG or KO?
By revenue growth (latest reported year), Genius Sports Limited (GENI) is pulling ahead at 31.
0% versus -26. 6% for High Roller Technologies, Inc. (ROLR). On earnings-per-share growth, the picture is similar: Sportradar Group AG grew EPS 200. 0% year-over-year, compared to -63. 0% for Genius Sports Limited. Over a 3-year CAGR, DKNG leads at 39. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ROLR or GENI or SRAD or DKNG or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -16. 7% for Genius Sports Limited — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -27. 8% for ROLR. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ROLR or GENI or SRAD or DKNG or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Sportradar Group AG (SRAD) is the more undervalued stock at a PEG of 0. 71x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, The Coca-Cola Company (KO) trades at 25. 3x forward P/E versus 122. 9x for DraftKings Inc. — 97. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GENI: 37. 2% to $9. 40.
08Which pays a better dividend — ROLR or GENI or SRAD or DKNG or KO?
In this comparison, KO (2.
5% yield) pays a dividend. ROLR, GENI, SRAD, DKNG do not pay a meaningful dividend and should not be held primarily for income.
09Is ROLR or GENI or SRAD or DKNG or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). High Roller Technologies, Inc. (ROLR) carries a higher beta of 2. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ROLR and GENI and SRAD and DKNG and KO?
These companies operate in different sectors (ROLR (Consumer Cyclical) and GENI (Communication Services) and SRAD (Technology) and DKNG (Consumer Cyclical) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ROLR is a small-cap deep-value stock; GENI is a small-cap high-growth stock; SRAD is a small-cap quality compounder stock; DKNG is a mid-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while ROLR, GENI, SRAD, DKNG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.